Global Veterinary Intelligence
Reader login
Veterinary33

Free reader access

Every article remains open. Registration is for participation, not access.

Create a profile to comment, join discussions, receive more relevant recommendations, keep your activity connected, and access selected opportunities.

Company · Clinical Study · 2 min read

ImpriMed Announces Findings on the Value of Personalized Cancer Care for Dogs

Loading views…

Industry development with potential relevance for veterinary professionals, companion animal care, and animal health stakeholders.

October 5, 2026 at 1:00 PM UTCBusiness Wire VeterinaryVeterinary33 Editorial Desk

Comments on this article are also part of the Veterinary33 clinical forum.

ImpriMed Announces Findings on the Value of Personalized Cancer Care for Dogs
Business Wire Veterinary

Digital tools are becoming increasingly important across veterinary medicine, from clinical workflows to client communication and practice operations.

According to the announcement, ImpriMed Announces Findings on the Value of Personalized Cancer Care for Dogs. The development is relevant because it reflects how animal health companies, service providers, and technology platforms are responding to changing expectations in veterinary care.

What Was Announced

PALO ALTO, Calif.--( BUSINESS WIRE )-- ImpriMed, a precision medicine company using artificial intelligence and live-cell testing to inform cancer treatment decisions, today announced a new cost analysis highlighting the value of its Personalized Prediction Profile (PPP). Presented at the 2026 Veterinary Cancer Society Annual Conference in Minneapolis, the analysis examined treatment costs alongside outcomes in dogs whose lymphoma had returned after chemotherapy.

Precision medicine should help veterinarians make informed decisions for each patient and help families understand the value of continued care Using data from a previously published clinical study, researchers found that when the chosen treatments more closely aligned with PPP predictions, the outcomes were associated with more time without cancer worsening and a 38% lower estimated treatment cost per day during that period. “These findings connect personalized treatment selection with longer disease control and show why treatment costs should be considered alongside patient outcomes.” For veterinarians and families facing a dog’s cancer relapse, choosing the next treatment involves weighing its potential benefit and financial commitment.

Why This Matters for Veterinary Professionals

For veterinary professionals, technology announcements matter when they affect efficiency, access to care, diagnostics, reimbursement, or the daily workflow of the clinic.

At the practice level, the most relevant question is whether the development can reduce administrative friction, improve access to information, or support more consistent communication between veterinary teams and clients.

Industry Perspective

The animal health industry continues to move toward more connected, data-driven services for veterinary practices and pet owners.

While individual announcements should be interpreted in the context of their source, they can help veterinary professionals monitor where investment, innovation, and market attention are moving across the animal health sector.

Original announcement: ImpriMed — https://www.businesswire.com/news/home/20260929845352/en/ImpriMed-Announces-Findings-on-the-Value-of-Personalized-Cancer-Care-for-Dogs

Join this discussion

Add your reply

Share a professional insight, ask a focused question, or add relevant clinical experience.

Member participation

Log in to join the discussion

Share an answer, ask a question, reply to another professional, or mark useful contributions as helpful.

Log in to reply

Continue the conversation

Share this article with another veterinary professional.

LinkedInEmail